Balancing role of nitric oxide in complement-mediated activation of platelets from mCd59a and mCd59b double-knockout mice

American Journal of Hematology

Volumn 84, Issue 4, 2009, Pages 221-227

  Qin, Xuebin ^a,b   Hu, Weiguo ^a,b   Song, Wenping ^b   Blair, Price ^c   Wu, Gongxiong ^b   Hu, Xuemei ^b   Song, Yanli ^a   Bauer, Selena ^c   Feelisch, Martin ^c   Leopold, Jane A ^a   Loscalzo, Joseph ^a   Halperin, Jose A ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,3 BIS(2 AMINOETHYL) 1 HYDROXY 2 OXOTRIAZENE; CD59 ANTIGEN; COMPLEMENT COMPONENT C3; N ACETYL S NITROSOPENICILLAMINE; N(G) NITROARGININE METHYL ESTER; NITRATE; NITRIC OXIDE; NITRITE; PADGEM PROTEIN; VON WILLEBRAND FACTOR; CD59A PROTEIN, MOUSE; CD59B PROTEIN, MOUSE; COMPLEMENT MEMBRANE ATTACK COMPLEX; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; NITROSO DERIVATIVE;

ANIMAL CELL; ARTICLE; BLEEDING TIME; COMPLEMENT DEFICIENCY; IN VIVO STUDY; KNOCKOUT MOUSE; MOUSE; NITROGEN BALANCE; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOSIS; ANIMAL; BLOOD; COMPLEMENT ACTIVATION; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; IMMUNOLOGY; MOUSE MUTANT; PHYSIOLOGY; THROMBOCYTE; THROMBOPHILIA;

ANIMALS; ANTIGENS, CD59; BLOOD PLATELETS; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT MEMBRANE ATTACK COMPLEX; DISEASE MODELS, ANIMAL; HEMOGLOBINURIA, PAROXYSMAL; MICE; MICE, KNOCKOUT; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE; NITROSO COMPOUNDS; PLATELET ACTIVATION; S-NITROSO-N-ACETYLPENICILLAMINE; THROMBOPHILIA;

EID: 64549137026     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21363     Document Type: Article

References (45)

1. Morgan BP, Harris CL. Complement Regulatory Proteins. London: Academic Press; 1999.
2. Walport MJ. Complement. First of two parts. N Engl J Med 2001;344:1058-1066.
3. Walport MJ. Complement. Second of two parts. N Engl J Med 2001;344:1140-1144.
4. Zhou X, Hu W, Qin X. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist 2008;13:954-966.
5. Acosta J, Qin X, Halperin J. Complement and complement regulatory proteins as potential molecular targets for vascular diseases. Curr Pharm Des 2004;10:203-211. (Pubitemid 38072756)
6. Hillmen P, Richards SJ. Implications of recent insights into the pathophysiology of paroxysmal nocturnal haemoglobinuria. Br J Haematol 2000;108:470-479. (Pubitemid 30196240)
7. Luzzatto L, Bessler M. The dual pathogenesis of paroxysmal nocturnal hemoglobinuria. Curr Opin Hematol 1996;3:101-110. (Pubitemid 26178048)
8. Takeda J, Miyata T, Kawagoe K, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993;73:703-711.
9. Sims PJ, Faioni EM, Wiedmer T, Shattil SJ. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem 1988;263:18205-18212. (Pubitemid 19005097)
10. Wiedmer T, Hall SE, Ortel TL, et al. Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. Blood 1993;82:1192-1196.
11. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 2005;293:1653-1662. (Pubitemid 40471796)
12. Holt DS, Botto M, Bygrave AE, et al. Targeted deletion of the CD59 gene causes spontaneous intravascular hemolysis and hemoglobinuria. Blood 2001;98:442-449.
13. Qin X, Krumrei N, Grubissich L, et al. Deficiency of the mouse complement regulatory protein mCd59b results in spontaneous hemolytic anemia with platelet activation and progressive male infertility. Immunity 2003;18:217-227.
14. Qin X, Hu W, Song W, et al. Generation and phenotyping of mCd59a and mCd59b double-knockout mice. Am J Hematol 2008;84:65-70.
15. Qin X, Dobarro M, Bedford SJ, et al. Further characterization of reproductive abnormalities in mCd59b knockout mice: a potential new function of mCd59 in male reproduction. J Immunol 2005;175:6294-6302.
16. Qian YM, Qin X, Miwa T, et al. Identification and functional characterization of a new gene encoding the mouse terminal complement inhibitor CD59. J Immunol 2000;165:2528-2534.
17. Qin X, Miwa T, Aktas H, et al. Genomic structure, functional comparison, and tissue distribution of mouse Cd59a and Cd59b. Mamm Genome 2001;12:582-589.
18. Baalasubramanian S, Harris CL, Donev RM, et al. CD59a is the primary regulator of membrane attack complex assembly in the mouse. J Immunol 2004;173:3684-3692.
19. Harker LA, Slichter SJ. The bleeding time as a screening test for evaluation of platelet function. N Engl J Med 1972;287:155-159.
20. Hu W, Ferris SP, Tweten RK, et al. Rapid conditional targeted ablation of cells expressing human CD59 in transgenic mice by intermedilysin. Nat Med 2008;14:98-103.
21. Mustard JF, Packham MA, Kinlough-Rathbone RL, et al. Fibrinogen and ADP-induced platelet aggregation. Blood 1978;52:453-466.
22. Nossel HL, Wilner GD, Drillings M. Inhibition of collagen-induced platelet aggregation by normal plasma. J Clin Invest 1971;50:2168-2175.
23. Bellander BM, Singhrao SK, Ohlsson M, et al. Complement activation in the human brain after traumatic head injury. J Neurotrauma 2001;18:1295-1311.
24. Mollnes TE, Garred P, Bergseth G. Effect of time, temperature and anticoagulants on in vitro complement activation: consequences for collection and preservation of samples to be examined for complement activation. Clin Exp Immunol 1988;73:484-488. (Pubitemid 18228157)
25. Gorbet MB, Sefton MV. Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. Biomaterials 2004;25:5681-5703. (Pubitemid 38624449)
26. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987;2:1057-1058. (Pubitemid 17154788)
27. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res 2001;88:756-762. (Pubitemid 32429970)
28. Dole VS, Bergmeier W, Mitchell HA, et al. Activated platelets induce Weibel-Palade-body secretion and leukocyte rolling in vivo: role of P-selectin. Blood 2005;106:2334-2339. (Pubitemid 41510804)
29. Shibuta S, Mashimoto T, Ohara A, et al. Intracerebroventricular administration of a nitric oxide-releasing compound, NOC-18, produces thermal hyperalgesia in rats. Neurosci Lett 1995;187:103-106.
30. Jansen A, Drazen J, Osborne JA, et al. The relaxant properties in guinea pig airways of S-nitrosothiols. J Pharmacol Exp Ther 1992;261:154-160.
31. Grunewald M, Grunewald A, Schmid A, et al. The platelet function defect of paroxysmal nocturnal haemoglobinuria. Platelets 2004;15:145-154.
32. Qin X, Ferris S, Hu W, et al. Analysis of the promoters and 50-UTR of mouse Cd59 genes, and of their functional activity in erythrocytes. Genes Immun 2006;7:287-297.
33. Wiedmer T, Sims PJ. Participation of protein kinases in complement C5b-9-induced shedding of platelet plasma membrane vesicles. Blood 1991;78:2880-2886.
34. van der Zee PM, Biro E, et al. P-selectin- and CD63-exposing platelet microparticles reflect platelet activation in peripheral arterial disease and myocardial infarction. Clin Chem 2006;52:657-664.
35. Del Conde I, Cruz MA, Zhang H, et al. Platelet activation leads to activation and propagation of the complement system. J Exp Med 2005;201:871-879.
36. Feelisch M, Brands F, Kelm M. Human endothelial cells bioactivate organic nitrates to nitric oxide: implications for the reinforcement of endothelial defence mechanisms. Eur J Clin Invest 1995;25:737-745.
37. Kleinbongard P, Schulz R, Rassaf T, et al. Red blood cells express a functional endothelial nitric oxide synthase. Blood 2006;107:2943-2951.
38. Gladwin MT, Crawford JH, Patel RP. The biochemistry of nitric oxide, nitrite, and hemoglobin: role in blood flow regulation. Free Radic Biol Med 2004;36:707-717. (Pubitemid 38264415)
39. Qin X, Goldfine A, Krumrei N, et al. Glycation inactivation of the complement regulatory protein CD59: a possible role in the pathogenesis of the vascular complications of human diabetes. Diabetes 2004;53:2653-2661.
40. Taka T, Ono H, Sasaki Y, et al. Platelet reactivity in spontaneously diabetic rats is independent from blood glucose and insulin levels. Platelets 2002;13:313-316.
41. Tan KT, Tayebjee MH, Lim HS, Lip GY. Clinically apparent atherosclerotic disease in diabetes is associated with an increase in platelet microparticle levels. Diabet Med 2005;22:1657-1662. (Pubitemid 43046464)
42. Lee KA, Kim MS. Antiplatelet and antithrombotic activities of methanol extract of Usnea longissima. Phytother Res 2005;19:1061-1064. (Pubitemid 43133465)
43. Miranda KM, Katori T, Torres de Holding CL, et al. Comparison of the NO and HNO donating properties of diazeniumdiolates: primary amine adducts release HNO in Vivo. J Med Chem 2005;48:8220-8228.
44. Sudo T, Ito H, Kimura Y. Characterization of platelet aggregation in whole blood of laboratory animals by a screen filtration pressure method. Platelets 2003;14:239-246. (Pubitemid 36791844)
45. Reheman A, Yang H, Zhu G, et al. Plasma fibronectin depletion enhances platelet aggregation and thrombus formation in mice lacking fibrinogen and von Willebrand factor. Blood 2008.